secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAGENICS INC (OGEN)
CIK:        0001174940
Form:       8-K
Filed at:   2025-10-21T23:59:59+00:00
Accession:  0001493152-25-018725
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 3.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oragenics settles Ladenburg dispute for $700K; regains NYSE American compliance
-------------------------------------------------------------------------------

- Paid $700K to Ladenburg Thalmann to settle $2.5M fee dispute; mutual release and arbitration dismissal.
- Regained compliance with NYSE American Section 1003(a) as stockholders' equity exceeds $6M as of Oct 18, 2025.
- Compliance restored after $16.5M Series H Preferred Stock offering in July 2025; .BC indicator to be removed.
- Company now focusing on advancing ONP-002 concussion treatment into Phase IIa trials in Australia and planning U.S. Phase IIb.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1174940/000149315225018725/0001493152-25-018725-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1174940/000149315225018725/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-018725

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer